CN103202483A - Nutritional composition for calcium supplement - Google Patents
Nutritional composition for calcium supplement Download PDFInfo
- Publication number
- CN103202483A CN103202483A CN2012100073183A CN201210007318A CN103202483A CN 103202483 A CN103202483 A CN 103202483A CN 2012100073183 A CN2012100073183 A CN 2012100073183A CN 201210007318 A CN201210007318 A CN 201210007318A CN 103202483 A CN103202483 A CN 103202483A
- Authority
- CN
- China
- Prior art keywords
- calcium
- alimentation composition
- omega
- fatty acid
- unsaturated fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a nutritional composition for calcium supplement. The nutritional composition includes Ca, P and omega-3 unsaturated fatty acid, the Ca:P ratio is 1.3-2.5:1, the Ca:omega-3 unsaturated fatty acid ratio is 1:0.2-4, a mineral matter calcium source comprises one or a plurality of milk mineral, calcium carbonate, calcium gluconate, calcium amino acid chelate, calcium phosphate, calcium hydrogen phosphate and calcium lactate, and a mineral matter phosphorus sauce comprises one or a plurality of milk mineral, calcium phosphate and calcium hydrogen phosphate. A pharmaceutically or bromatologically acceptable carrier is added to the above raw materials to prepare various oral liquid preparations or solid and semisolid preparations. The nutritional composition having the above combination has the advantages of full performance of the respective efficacies of above three nutrients, synergistic effect of the three nutrients, improvement of the absorption rate of Ca in the body, and increase of the bioavailability of Ca, makes an eater still have a good effect without reverse after the supplementation of the nutritional composition is stopped for a long time, especially overcomes the easy appearing disadvantage of calculi caused by present calcium preparations, and realizes the efficacy of no kidney (or urinary system) calculi during the calcium supplementation.
Description
Technical field
The invention belongs to the health food technology field, specifically is a kind of calcium-supplementing nutritive composition.
Background technology
Calcium is to keep one of human nerve, muscle, skeletal system, cell membrane and the necessary important macroelement of capillary permeability normal function, has very important physical, biochemical function, and human body all needs calcium in whole life process.The main source of calcium is food in the human body, because the imbalance of diet structure, the absorption of calcium generally lacks in the human body, therefore needs on the logical diet basis to replenish the calcium by calcium preparation.But scientific research finds that calcium also is to promote one of lithogenous factor.The calcium of Excessive Intake helps the formation of calculus in the meals, long-term excessive additional calcium preparation and vitamin D goods, with the absorption that promotes calcium at small intestine, cause the too high and urine calcium discharge increase of blood calcium, may cause bad reactions such as milk-alkali syndrome, belch, constipation, even diseases such as hypercalcemia, alkalosis occur, and then increase the danger that calculi in urinary system takes place.
The formation of calculi in urinary system is that crystalline solid concentration raises or the solubility reduction in the urine because some factor causes, and makes urine present hypersaturated state, separates out crystallization and in local growth, gathering, finally forms calculus.In this process, the minimizing of crystallization inhibitor contents is two key factors in the formation of urine crystalline solid hypersaturated state and the urine.The generation of calculi in urinary system with strictly speaking with heredity, eating habit, life style, infect, multiple factor such as drug side-effect is relevant, but summary is got up to influence calcium and is absorbed in vivo, utilization is that organic factor and dietary factors are two big principal elements, body condition often varies with each individual, be can't be by the factor of human intervention control, different bodies is to the absorption of the calcium of absorption equivalent, utilization rate is all different, therefore, even different bodies is in rational absorption scope, the same calcium preparation of excessive use can't not got rid of this calcium preparation yet increases the possibility of calculi in urinary system to it, and dietary factors can be intervened by artificial adjustment.
And calcium preparation is on the market generally made compound formulation with the calcium salt that a kind of calcium salt of high calcium content is made simple preparation or multiple low calcium content, and normal and vitamin D carries out composite to promote calcium to absorb, often ignore in the preparation process of calcium preparation and suppress the lithogenous factor and carry out scientific and reasonable compositely, increased lithogenous possibility.Therefore general calcium preparation need be taken cautiously, special populations such as calculi in urinary system (as kidney stone, lithangiuria) patient, infant and the elderly especially, and the safety that these crowds replenish necessity of calcium and additional calcium preparation has just become two aspects of contradiction.
Summary of the invention
The purpose of this invention is to provide a kind of advantages of good calcium supplying effect, i.e. high absorption, high usage, and can not cause or have and reduce or the calcium-supplementing nutritive composition of prevention calculi in urinary system.
Realize the calcic alimentation composition with prevention calculi in urinary system effect of the present invention specifically:
A kind of calcium-supplementing nutritive composition comprises mineral calcium, phosphorus and omega-3 unsaturated fatty acid, and three's relationship between quality is: calcium: phosphorus is 1.3-2.5: 1; Calcium: omega-3 unsaturated fatty acid is 1: 0.2--4;
The proportionate relationship of above-mentioned alimentation composition is: calcium: phosphorus is 1.5-2.2: 1; Calcium: omega-3 unsaturated fatty acid is 1: 0.5--3;
The proportionate relationship of above-mentioned alimentation composition is: calcium: phosphorus is 1.8-2: 1; Calcium: omega-3 unsaturated fatty acid is 1: 0.5--2;
The proportionate relationship of above-mentioned alimentation composition is: calcium: phosphorus is 2: 1; Calcium: omega-3 unsaturated fatty acid is 1: 1;
Above-mentioned alimentation composition mineral calcium source is: comprise in newborn mineral salt, calcium carbonate, calcium gluconae, amino acid chelated calcium, calcium phosphate, calcium monohydrogen phosphate, the calcium lactate one or more;
Above-mentioned alimentation composition mineral phosphorus source is: comprise in newborn mineral salt, calcium phosphate, the calcium monohydrogen phosphate one or more;
Above-mentioned alimentation composition, calcium phosphorus source is newborn mineral salt, omega-3 unsaturated fatty acid is linseed oil;
The omega-3 unsaturated fatty acid source is in the above-mentioned alimentation composition: one or more in linseed meal or linseed oil, fish oil or fish oil powder, algae oil or the algae oil-bound distemper;
Also contain antioxidant in the above-mentioned alimentation composition and be in vitamin E, vitamin C, TBHQ, Rosmarinus officinalis extract, the Tea Polyphenols one or more;
Above-mentioned alimentation composition also contains short calcium enhancer: one or more among vitamin D, CPP, the CBP;
A kind of alimentation composition preparation contains the above-mentioned alimentation composition of prevention or treatment effective dose and acceptable carrier pharmaceutically or on the food;
Above-mentioned alimentation composition preparation, described preparation can be any oral liquid formulation or solid, semisolid preparation, comprise chewable tablets, Film coated tablets, capsule, soft capsule, pulvis, granule;
Above-mentioned alimentation composition is preparing replenishing vitamins and mineral matter, is promoting skeleton development or prevent and treat osteoporosis, and the application in minimizing or prevention calculi in urinary system medicine or the nutrient and healthcare products.
Calcic alimentation composition of the present invention, determined the formula ratio of three kinds of compositions, such combination has not only guaranteed three's nutrients giving full play to of effect separately, and the effect of Synergistic arranged each other, thereby not only improved the absorptivity of calcium at body, also increased the bioavailability of calcium, the eater is not taken a turn for the worse than still having good bone-forming effect in the long time after stopping supplementary copy invention alimentation composition, the more important thing is, such combination can realize reducing or preventing the effect of calculi in urinary system, overcome the drawback that existing calcium preparation easily causes calculus, but make all safety of different crowd, effectively, take expediently, especially can satisfy the infant, the pregnant woman, wet nurse and renal insufficiency, functions of intestines and stomach decline crowd waits the special physiological crowd to safety, the demand of effectively replenishing the calcium.
The specific embodiment
The present invention is further illustrated below in conjunction with embodiment, and following embodiment only is used for explanation technical scheme of the present invention, but to not restriction of the present invention.
Embodiment one
Taking by weighing mass percent is 10% calcium monohydrogen phosphate (2H
223%), 7.7% linseed oil-bound distemper (alpha-linolenic acid: 15%), 0.002% vitamin D powder (containing vitamin D 0.25%), 30% powdered glucose, 31.298% maltodextrin, 21% skimmed milk power O) (calcium:.
Namely get the nutrient combination medicinal powder after all supplementary materials are mixed.
Embodiment two
Taking by weighing mass percent is 10% calcium monohydrogen phosphate (5H
217.7%), 2.8% amino acid chelated calcium (calcium: 10%), 15.4% algae oil (DHA:40%), 0.002% vitamin D powder (containing vitamin D 0.25%), 0.01%TBHQ, 71.788% maltodextrin O) (calcium:.
Earlier with algae oil with the part maltodextrin by after the drying process with atomizing embedding, again with the powder after the embedding with other supplementary materials granulate, drying, behind compressing tablet, dressing, namely get the alimentation composition Film coated tablets.
Embodiment three
Taking by weighing mass percent is 10% calcium monohydrogen phosphate (2H
223%), 7.2% calcium lactate (calcium: 13%), 46% fish oil powder (omega-3 unsaturated fatty acid: 14%), 0.01% Tea Polyphenols, 36.59% dextrin, 0.2% dolomol O) (calcium:.
After above-mentioned supplementary material mixed, fill with the capsule filler, after polishing, packing, namely get the nutrient combination composite capsule.
Embodiment four
25%), 20% linseed oil (alpha-linolenic acid: 50%), 0.05%CPP, 0.02%VE, 3% lecithin, 36.93% peanut oil takes by weighing mass percent and is 40% milk calcium (calcium:.
After above-mentioned supplementary material mixed, make emulsification even three times after colloid mill; With gelatin: glycerine: after water=1:0.4:1 makes glue, add respectively in the encapsulating machine, namely get the nutrient combination composition soft capsule through pelleting, drying, after picking up ball, packing.
Embodiment five
38%), 6.7% calcium gluconae (calcium: 9%), 22% algae oil-bound distemper (DHA:10%), 31.07% skimmed milk power, 30% xylitol, 0.01% Rosmarinus officinalis extract, 0.02% CPP, 0.2% dolomol takes by weighing mass percent and is 10% calcium phosphate (calcium:.
After above-mentioned supplementary material mixed, through granulating, namely getting the nutrient combination composition chewable tablet behind dry, the compressing tablet.
Embodiment six
38%), 3% calcium carbonate (calcium: 40%), 20% linseed meal (alpha-linolenic acid: 5%), 36.3% skimmed milk power, 30% maltodextrin, 0.5% CBP, 0.2% VC takes by weighing mass percent and is 10% calcium phosphate (calcium:.
After above-mentioned supplementary material mixed, through granulating, namely getting the nutrient combination composition granule after dry, the packing.
Embodiment seven
70%), 0.3%CPP, 0.2%VE, 2.5% lecithin, 2% beeswax 38%), 65% deep sea fish oil takes by weighing mass percent and is 30% calcium phosphate (calcium:: (omega-3 unsaturated fatty acid:.
After above-mentioned supplementary material mixed, use twice of colloid mill emulsification again; With gelatin: glycerine: after water=1:0.4:1 makes glue, add respectively in the encapsulating machine, namely get the nutrient combination composition soft capsule through pelleting, drying, after picking up ball, packing.
Embodiment eight: animal experiment research
1, experiment material
The sample that makes by embodiment seven is as sample 1; Change the sample that makes after the soybean oil into by embodiment seven but with deep sea fish oil as sample 2; Lure stone agent (1% ethylene glycol adds 1% ammonium chloride water).45 of male Wistar rats, 3 monthly ages, body weight 200-250 gram.
2, animal experiment
Rat is divided into three groups at random, and every group of each 15 rat are labeled as A, B, C group respectively, these two groups of rats are fed raise respectively.
A organizes (control group): lure stone agent water and normal diet to stir and evenly mix with 2g and feed the arbitrary group of rat of raising in the experimental group at random;
B organizes (deep sea fish oil group): lure stone agent water and normal diet to stir and evenly mix with sample 1 and 2g and feed the arbitrary group of rat of raising in the experimental group at random;
C organizes (soybean oil group): lure stone agent water and normal diet to stir and evenly mix with sample 2 and 2g and feed one group of rat raising in the experimental group;
Rat adaptability under identical environment fed for 1 week, respectively organized rat subsequently 3 weeks and fed by above-mentioned feeding patterns and raise.1d collected the urine (1% Sodium azide is anticorrosion, 4 ℃ of preservations) of respectively organizing rat 24h with metabolic cage before experiment finished, and surveyed the urine amount, urinated total calcium, the solubility calcium after centrifugal; Experiment end after death uses 10% chloraldurate (volume fraction) 1ml lumbar injection, and serum creatinine, blood uric acid (experimental result sees Table) are surveyed from the cavity of resorption blood sampling in the anesthesia back; Vertical profile is respectively organized the two kidneys of rat, observes nephridial tissue size, form and pathological change under the mirror.
Table 2 group rat 24h urine, blood biochemical analysis result (
± s)
A organizes 15 19.36 ± 1.99 3262.3.7 ± 407.8 113.25 ± 13.1 55.25 ± 3.26 1.48 ± 0.18
B organizes 15 19.97 ± 2.36 2056.7 ± 265.8 73.25 ± 7.19 37.25 ± 2.13 2.52 ± 0.25
Data show in the table, and each organizes 24h urine amount difference does not have conspicuousness meaning (P＞0.05); The B group is compared urine total calcium (P＜0.05) with A, C group, and serum creatinine, blood uric acid, solubility calcium (P＜0.05) difference all have the conspicuousness meaning.
The nephridial tissue pathological change is dissected demonstration: A, B, two groups of kidneys of C all have profile to increase, the nephridial tissue oedema, but the B group obviously is lighter than A, C group.The no kidney stone of B group forms, and nephridial tissue clear in structure, skin medullary substance are demarcated clear, do not see calcium oxalate crystal in the tissue; A group kidney stone formation rate is 60% (9/15), and C group kidney stone formation rate is 53% (8/15), and as seen the kidney notacoria all is dispersed in dark white crystals and the calcified plaque of distribution.
In this experiment, B group rat nephridial tissue oedema is slight than A, C group, and cortex renis, medullary substance crystallization distribute and obviously be less than A, C group, and the nephridial tissue calcium content reduces, and illustrate to show that sample 1 composition of replenishing the calcium has prevention or suppresses the effect of kidney stone formation.
Show that by above-mentioned experimental data this composition of replenishing the calcium can be under the prerequisite of supplement calcium, the formation of prevention or inhibition kidney stone, the application facet of replenishing the calcium at special populations such as infant, calculi in urinary system patients have bigger meaning.
Claims (13)
1. a calcium-supplementing nutritive composition comprises mineral calcium, phosphorus and omega-3 unsaturated fatty acid, and three's relationship between quality is: calcium: phosphorus is 1.3-2.5: 1; Calcium: omega-3 unsaturated fatty acid is 1: 0.2--4.
2. alimentation composition according to claim 1 is characterized in that, described proportionate relationship is: calcium: phosphorus is 1.5-2.2: 1; Calcium: omega-3 unsaturated fatty acid is 1: 0.5--3.
3. alimentation composition according to claim 1 is characterized in that, described proportionate relationship is: calcium: phosphorus is 1.8-2: 1; Calcium: omega-3 unsaturated fatty acid is 1: 0.5--2.
4. alimentation composition according to claim 1 is characterized in that, described proportionate relationship is: calcium: phosphorus is 2: 1; Calcium: omega-3 unsaturated fatty acid is 1: 1.
5. alimentation composition according to claim 1 is characterized in that, the mineral calcium source is: comprise in newborn mineral salt, calcium carbonate, calcium gluconae, amino acid chelated calcium, calcium phosphate, calcium monohydrogen phosphate, the calcium lactate one or more.
6. alimentation composition according to claim 1 is characterized in that, mineral matter phosphorus source is: comprise in newborn mineral salt, calcium phosphate, the calcium monohydrogen phosphate one or more.
7. alimentation composition according to claim 1 is characterized in that, the omega-3 unsaturated fatty acid source is: one or more in linseed meal, linseed oil or linseed oil-bound distemper, fish oil or fish oil powder, algae oil or the algae oil-bound distemper.
8. alimentation composition according to claim 1 is characterized in that, calcium phosphorus source is newborn mineral salt, and omega-3 unsaturated fatty acid is linseed oil.
9. alimentation composition according to claim 1 is characterized in that, also contains antioxidant and be in vitamin E, vitamin C, TBHQ, Rosmarinus officinalis extract, the Tea Polyphenols one or more.
10. alimentation composition according to claim 1 is characterized in that, also contains short calcium enhancer: one or more among vitamin D, CPP, the CBP.
11. an alimentation composition preparation is characterized in that, contains each described alimentation composition of claim 1 to 9 of prevention or treatment effective dose and acceptable carrier pharmaceutically or on the food.
12. alimentation composition preparation according to claim 11 is characterized in that, described preparation can be any oral liquid formulation or solid, semisolid preparation, comprises chewable tablets, Film coated tablets, capsule, soft capsule, pulvis, granule.
13. each described alimentation composition of claim 1 to 12 is preparing replenishing vitamins and mineral matter, is promoting skeleton development or prevent and treat osteoporosis, and the application in minimizing or prevention calculi in urinary system medicine or the nutrient and healthcare products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100073183A CN103202483A (en) | 2012-01-11 | 2012-01-11 | Nutritional composition for calcium supplement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100073183A CN103202483A (en) | 2012-01-11 | 2012-01-11 | Nutritional composition for calcium supplement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103202483A true CN103202483A (en) | 2013-07-17 |
Family
ID=48750066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100073183A Pending CN103202483A (en) | 2012-01-11 | 2012-01-11 | Nutritional composition for calcium supplement |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103202483A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103392800A (en) * | 2013-08-20 | 2013-11-20 | 山东得益乳业股份有限公司 | High-calcium, low-fat, sucrose-free and solidification yoghurt and production method thereof |
| CN103599521A (en) * | 2013-11-08 | 2014-02-26 | 苏州冉新生物技术有限公司 | Vitamin D complex granules |
| CN104026239A (en) * | 2014-06-26 | 2014-09-10 | 光明乳业股份有限公司 | Bone-strengthened milk and preparation method thereof |
| CN104083402A (en) * | 2014-06-19 | 2014-10-08 | 吉林万通药业有限公司 | Calcium chewable tablet |
| CN105056216A (en) * | 2015-09-23 | 2015-11-18 | 北京里肯营养科学研究有限公司 | Calcium supplementing preparation/granule and preparation method thereof |
| CN105267239A (en) * | 2014-06-30 | 2016-01-27 | 北京斯利安制药有限公司 | Memory-improving and calcium-enriching algae oil DHA and calcium mixed preparation product |
| CN105831739A (en) * | 2016-03-31 | 2016-08-10 | 深圳市聚特佳生物科技有限公司 | Child edible calcium, ferrum and zinc chewable tablets |
| CN105982071A (en) * | 2015-02-05 | 2016-10-05 | 宁志伟 | High-dose vitamin D3 oral preparation recipe |
| CN106234600A (en) * | 2016-08-10 | 2016-12-21 | 湖北欣和生物科技有限公司 | Solid beverage rich in DHA algal oil meal |
| CN106262563A (en) * | 2016-08-25 | 2017-01-04 | 曾晓飞 | High-calcium fruit/vegetable nutrient supplement food rich in omega 3 |
| CN107773575A (en) * | 2016-08-31 | 2018-03-09 | 瑞普（天津）生物药业有限公司 | A kind of pet dog is replenished the calcium soft capsule prescription and preparation method thereof |
| CN107873994A (en) * | 2017-11-20 | 2018-04-06 | 江苏雅博动物健康科技有限责任公司 | One kind promotes bone growth milk powder and preparation method thereof |
| CN108552535A (en) * | 2018-04-08 | 2018-09-21 | 广州纽优生物科技有限公司 | calcium soft capsule and preparation method |
| CN108617834A (en) * | 2018-05-14 | 2018-10-09 | 汉臣氏（沈阳）儿童制品有限公司 | A kind of low-sugar type milk calcium walnut oil gel candy and preparation method thereof |
| CN109699889A (en) * | 2017-10-26 | 2019-05-03 | 内蒙古伊利实业集团股份有限公司 | A kind of composition and products thereof improving osteoporosis, preparation and application |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090490A (en) * | 1992-08-21 | 1994-08-10 | 斯科舍集团有限公司 | The treatment of fatty acid |
| CN1105205A (en) * | 1994-01-11 | 1995-07-19 | 黄升 | Nourishing food rich in DHA and active calcium for tonifying brain and benefiting intelligence and preparing process thereof |
| CN1209322A (en) * | 1997-08-21 | 1999-03-03 | 中国人民解放军国防科工委后勤部军事医学研究所 | Series product of high-effective neutral calcium-supplementary preparation |
| US6162472A (en) * | 1998-07-28 | 2000-12-19 | University Of Virginia Patent Foundation | Nutritional formula for premature infants and method of making |
| CN1406517A (en) * | 2001-08-28 | 2003-04-02 | 邓忠元 | Calcium sources with reasonable ratio of calcium and phosphorus and using food as raw materials |
| CN1631374A (en) * | 2003-12-24 | 2005-06-29 | 王林珍 | Safety compound biologic calcium formulation |
| WO2008111942A2 (en) * | 2006-04-18 | 2008-09-18 | Abbott Laboratories | Method of tailoring infant formulas to individual nutritional needs prior to use |
| CN101828707A (en) * | 2009-03-10 | 2010-09-15 | 上海培宝康实业股份有限公司 | Nutrition composition and application thereof |
| CN101890053A (en) * | 2009-05-19 | 2010-11-24 | 邓忠元 | Composite Chinese medicinal herb pure natural high-calcium preparation series |
-
2012
- 2012-01-11 CN CN2012100073183A patent/CN103202483A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090490A (en) * | 1992-08-21 | 1994-08-10 | 斯科舍集团有限公司 | The treatment of fatty acid |
| CN1105205A (en) * | 1994-01-11 | 1995-07-19 | 黄升 | Nourishing food rich in DHA and active calcium for tonifying brain and benefiting intelligence and preparing process thereof |
| CN1209322A (en) * | 1997-08-21 | 1999-03-03 | 中国人民解放军国防科工委后勤部军事医学研究所 | Series product of high-effective neutral calcium-supplementary preparation |
| US6162472A (en) * | 1998-07-28 | 2000-12-19 | University Of Virginia Patent Foundation | Nutritional formula for premature infants and method of making |
| CN1406517A (en) * | 2001-08-28 | 2003-04-02 | 邓忠元 | Calcium sources with reasonable ratio of calcium and phosphorus and using food as raw materials |
| CN1631374A (en) * | 2003-12-24 | 2005-06-29 | 王林珍 | Safety compound biologic calcium formulation |
| WO2008111942A2 (en) * | 2006-04-18 | 2008-09-18 | Abbott Laboratories | Method of tailoring infant formulas to individual nutritional needs prior to use |
| CN101828707A (en) * | 2009-03-10 | 2010-09-15 | 上海培宝康实业股份有限公司 | Nutrition composition and application thereof |
| CN101890053A (en) * | 2009-05-19 | 2010-11-24 | 邓忠元 | Composite Chinese medicinal herb pure natural high-calcium preparation series |
Non-Patent Citations (2)
| Title |
|---|
| 何建华等: "自由基与肾结石关系研究进展", 《广东医学》, no. 04, 25 April 2002 (2002-04-25) * |
| 王少刚等: "鱼油对尿石的防治作用", 《国外医学.泌尿系统分册》, no. 05, 25 May 2000 (2000-05-25) * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103392800A (en) * | 2013-08-20 | 2013-11-20 | 山东得益乳业股份有限公司 | High-calcium, low-fat, sucrose-free and solidification yoghurt and production method thereof |
| CN103599521A (en) * | 2013-11-08 | 2014-02-26 | 苏州冉新生物技术有限公司 | Vitamin D complex granules |
| CN104083402A (en) * | 2014-06-19 | 2014-10-08 | 吉林万通药业有限公司 | Calcium chewable tablet |
| CN104026239A (en) * | 2014-06-26 | 2014-09-10 | 光明乳业股份有限公司 | Bone-strengthened milk and preparation method thereof |
| CN105267239B (en) * | 2014-06-30 | 2019-08-09 | 北京斯利安药业有限公司 | A kind of mix preparation product of the algae oil DHA improving memory and supplement calcium and calcium |
| CN105267239A (en) * | 2014-06-30 | 2016-01-27 | 北京斯利安制药有限公司 | Memory-improving and calcium-enriching algae oil DHA and calcium mixed preparation product |
| CN105982071A (en) * | 2015-02-05 | 2016-10-05 | 宁志伟 | High-dose vitamin D3 oral preparation recipe |
| CN105056216A (en) * | 2015-09-23 | 2015-11-18 | 北京里肯营养科学研究有限公司 | Calcium supplementing preparation/granule and preparation method thereof |
| CN105831739A (en) * | 2016-03-31 | 2016-08-10 | 深圳市聚特佳生物科技有限公司 | Child edible calcium, ferrum and zinc chewable tablets |
| CN106234600A (en) * | 2016-08-10 | 2016-12-21 | 湖北欣和生物科技有限公司 | Solid beverage rich in DHA algal oil meal |
| CN106262563A (en) * | 2016-08-25 | 2017-01-04 | 曾晓飞 | High-calcium fruit/vegetable nutrient supplement food rich in omega 3 |
| CN107773575A (en) * | 2016-08-31 | 2018-03-09 | 瑞普（天津）生物药业有限公司 | A kind of pet dog is replenished the calcium soft capsule prescription and preparation method thereof |
| CN109699889A (en) * | 2017-10-26 | 2019-05-03 | 内蒙古伊利实业集团股份有限公司 | A kind of composition and products thereof improving osteoporosis, preparation and application |
| CN107873994A (en) * | 2017-11-20 | 2018-04-06 | 江苏雅博动物健康科技有限责任公司 | One kind promotes bone growth milk powder and preparation method thereof |
| CN108552535A (en) * | 2018-04-08 | 2018-09-21 | 广州纽优生物科技有限公司 | calcium soft capsule and preparation method |
| CN108617834A (en) * | 2018-05-14 | 2018-10-09 | 汉臣氏（沈阳）儿童制品有限公司 | A kind of low-sugar type milk calcium walnut oil gel candy and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103202483A (en) | Nutritional composition for calcium supplement | |
| RU2375079C2 (en) | Polyvitaminic and mineral food additives | |
| CN103190615A (en) | Liquid calcium soft capsules and preparation method thereof | |
| CN105056216A (en) | Calcium supplementing preparation/granule and preparation method thereof | |
| CN108185437A (en) | A kind of full nutrient formulation powder of tumour and preparation method thereof | |
| EA019348B1 (en) | Method for treating hyperglycemia by a combination of 25-hydroxyvitamin d3 and vitamin d | |
| CN108391811A (en) | A kind of tumour full nutrition formula food and its application | |
| JP2010503387A (en) | Feed supplement composition containing one or more vitamin D3 compounds and one or more magnesium salts | |
| CN101279089B (en) | Donkey-hide gelatin calcium composition and preparing process thereof | |
| CN105581331B (en) | Calcium supplement nutritional composition | |
| RU2309751C1 (en) | Method for treating the disorders of mineral metabolism at arthritis, or osteochondrosis, or rickets, or arthrosis, or osteoporosis | |
| US8491889B1 (en) | Method for reducing micronutrient competitions | |
| CA2395530C (en) | Calcium formate for use as a phosphorus binder and a dietary supplement | |
| CN105288579A (en) | Calcium supplement agent and preparation method thereof | |
| CN1774179A (en) | Multi-vitamin and mineral supplement for pregnant women | |
| JP2008531027A (en) | Reduced digestibility of phosphorus in animal nutrition | |
| JP2008237058A (en) | Dietary supplement | |
| CN108851037A (en) | A kind of preparation method and its usage of nephrotic syndrome wholefood | |
| CN101129406A (en) | Formula of compound colla carapaeis corii asini series products and method for producing the same | |
| CN1247199C (en) | Nutrition supplement agent | |
| CN107136490A (en) | A kind of peptide Chinese caterpillar fungus health product | |
| CN101708184B (en) | Medicine application of iron liposome | |
| CN105831730A (en) | Krill oil composite special dietary food for reducing hypertension, hyperglycemia and hyperlipidemia | |
| CN100364969C (en) | Water soluble vitamins D2 preparation method | |
| CN109805390A (en) | A kind of calcium nervonate, nervonic acid zinc and vitamin K2Compound composition soft capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130717 |
|
| RJ01 | Rejection of invention patent application after publication |